Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02396212
Other study ID # CACZ885G1301
Secondary ID 2018-002355-15
Status Completed
Phase Phase 3
First received
Last updated
Start date May 7, 2015
Est. completion date August 1, 2018

Study information

Verified date August 2019
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This was a phase III study designed to provide efficacy and safety data for canakinumab administered for at least 48 weeks as subcutaneous (s.c.) injection every 4 weeks (q4wk) in Japanese patients with Systemic Juvenile Idiopathic Arthritis (SJIA). Interim analysis (IA) data at Week 28 and 48 from this study supported a registration submission of canakinumab in the indication of SJIA in Japan.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date August 1, 2018
Est. primary completion date March 7, 2017
Accepts healthy volunteers No
Gender All
Age group 2 Years to 19 Years
Eligibility Inclusion Criteria

- Confirmed diagnosis of SJIA as per International League Against Rheumatism (ILAR) definition (Petty, et al. 2004) that must have occurred at least 3 months prior to enrollment with an onset of disease < 16 years of age: Arthritis in one or more joints, with or preceded by fever of at least 2 weeks duration that is documented to be daily/quotidian for at least 3 days and accompanied by one or more of the following: Rash due to SJIA, lymphadenopathy, Hepatomegaly/Splenomegaly, Serositis

- Active disease at the time of baseline defined as follows:

- At least 2 joints with active arthritis

- Documented spiking, intermittent fever (body temperature > 38°C) for at least 1 day during the screening epoch and within 1 week before first canakinumab dose

- C-Reactive Protein (CRP) > 30 mg/L(3 mg/dL) (normal range < 10 mg/L(1 mg/dL))

- Negative TB screen (Chest X-ray and T-SPOT test)

Exclusion Criteria:

- With active or recurrent bacterial, fungal or viral infection at the time of enrollment, including patients with evidence of Human Immunodeficiency Virus (HIV) infection, Hepatitis B and Hepatitis C infection. Patients with resolved/previous hepatitis B infection (a negative HBs antigen, but a positive anti-HBs antibody and/or anti-HBc antibody).

- With underlying metabolic, renal, hepatic, infectious or gastrointestinal conditions which in the opinion of the investigator immunocompromises the patient and /or places the patient at unacceptable risk for participation.

- With neutropenia (absolute neutrophil count < 1500/mm3) at screening.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Canakinumab
canakinumab was provided as a 150 mg/1 mL solution for subcutaneous injection and administered at 4mg/kg every 4 weeks.

Locations

Country Name City State
Japan Novartis Investigative Site Chiba-city Chiba
Japan Novartis Investigative Site Kagoshima city Kagoshima
Japan Novartis Investigative Site Kanazawa-city Ishikawa
Japan Novartis Investigative Site Obu Aichi
Japan Novartis Investigative Site Sendai-city Miyagi
Japan Novartis Investigative Site Yokohama-city Kanagawa
Japan Novartis Investigative Site Yokohama-city Kanagawa

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Who Achieved a Minimum Adapted American College of Rheumatology (ACR) Pediatric 30 Criteria Minimum Adapted ACR Pediatric 30 criteria is defined as improvement from baseline at least 30% in at least 3 of response variables 1 to 6 in Adapted ACR Pediatric response variables and no intermittent fever (i.e. axillary, oral, or rectal body temperature = 38°C) in the preceding week (variable 7), with no more than one variable 1-6 worsening by more than 30%. Adapted ACR Pediatric response variables consists of following 7 variables: 1. Physician's Global Assessment of disease activity on a 0-100 mm VAS; 2. Parent's or Patient's (if appropriate in age) Global Assessment of Patient's overall wellbeing based upon the 0-100 mm VAS in the Child Health Assessment Questionnaire (CHAQ); 3. Functional ability: CHAQ; 4. Number of joints with active arthritis; 5. Number of joints with limitation of motion; 6. Laboratory measure of inflammation: CRP (mg/L); 7. Absence of intermittent fever due to SJIA during the preceding week. Week 8
Primary Percentage of Participants With Canakinumab Treatment Who Were Able to Taper Corticosteroids Successfully To evaluate the percentage of participants with canakinumab treatment who were able to taper corticosteroids successfully at Week 28 Week 28
Secondary Percentage of Participants Who Met the Adapted ACR Pediatric 30/50/70/90/100 Criteria of Canakinumab Over Time Adapted ACR Pediatric 30/50/70/90/100 criteria was assessed based on the following 7 variables: 1. Physician's Global Assessment of disease activity on a 0-100 mm VAS; 2. Parent's or Patient's (if appropriate in age) Global Assessment of Patient's overall wellbeing based upon the 0-100 mm VAS in the CHAQ; 3. Functional ability: CHAQ; 4. Number of joints with active arthritis; 5. Number of joints with limitation of motion; 6. Laboratory measure of inflammation: CRP (mg/L); 7. Absence of intermittent fever due to SJIA during the preceding week. Response was defined as more than or equal to (=) 30%/50%/70%/90% or 100% improvement in at least 3 of 6 response variables and no intermittent fever in the preceding week (variable 7) with no more than one variable 1-6 worsening by more than 30%. Weeks 4, 8, 28, 48, 96, 144, end of study (EOS) (up to Week 164)
Secondary Absolute Change From Baseline in the Adapted ACR Pediatric Criteria of Canakinumab Over Time: ACR Component: Physician's Global Assessment of Disease Activity ACR component, Physician's Global Assessment of disease activity on a 0 - 100 mm VAS by visit is the first response ACR variable in the ACR pediatric criteria. The VAS scale ranges from no disease activity (0 mm) to very severe disease activity (100 mm). Lower scale indicates decreased disease activity. Change from baseline was calculated by subtracting baseline value from post baseline value. Baseline, Weeks 4, 8, 28, 48, 96, 144, EOS (up to Week 164)
Secondary Absolute Change From Baseline in the Adapted ACR Pediatric Criteria of Canakinumab Over Time: ACR Component: CHAQ: Parent's or Patient's Global Assessment of Patient's Overall Well-being as Part of CHAQ ACR component, Parent's or Patient's (if appropriate in age)Global Assessment of patient's overall well-being as part of CHAQ on a 0 - 100 mm VAS by visit is the second response variable in the ACR pediatric criteria. The VAS scale ranges from 0-100 mm, from very well (0 mm) to very poor (100 mm). Lower scale indicates improvement of patient's overall well-being. Absolute change is calculated by subtracting baseline value from post baseline value. Baseline, Weeks 4, 8, 28, 48, 96, 144, EOS up to Week 164
Secondary Absolute Change From Baseline in the Adapted ACR Pediatric Criteria of Canakinumab Over Time: ACR Component: CHAQ: Functional Ability Score Disability Score as part of CHAQ per functional ability score (range from 0 to 3) is one of the variable in the ACR ped criteria. The CHAQ was used to assess physical ability & functional status of patients as well as quality of life. The disability dimension consists of 20 multiple choice items concerning difficulty in performing 8 common activity categories of daily living: dressing & grooming, arising, eating, walking, reaching, personal hygiene, gripping & other "activities". Subjects choose from 4 responses, ranging from 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) & 3 (unable to do). Standard Disability Index (SDI) was computed by summing up the computed scores for each activity category and dividing by the number of categories answered. The lower the response the more positive the results & the higher the response, the less positive the results. Change from baseline was calculated by subtracting baseline value from post baseline value. Baseline, Weeks 4, 8, 28, 48, 96, 144, EOS (up to Week 164)
Secondary Absolute Change From Baseline in the Adapted ACR Pediatric Criteria of Canakinumab Over Time: ACR Component: Number of Joints With Active Arthritis ACR component, Number of joints with active arthritis was assessed as the forth response variables of ACR Pediatric Criteria. Baseline, Weeks 4, 8, 28, 48, 96, 144, EOS (up to Week 164)
Secondary Absolute Change From Baseline in the Adapted ACR Pediatric Criteria of Canakinumab Over Time: ACR Component: Number of Joints With Limitation of Motion ACR component, Number of joints with limitation of motion is the fifth response variable in the ACR ped criteria. Baseline, Weeks 4, 8, 28, 48, 96, 144, EOS (up to Week 164)
Secondary Number of Participants Having Fever in the Adapted ACR Pediatric Criteria of Canakinumab Over Time ACR component, Number of participants having fever is the seventh response variable in the ACR ped criteria. Baseline, Day 3, Weeks 2, 8, 28, 48, 56, 96, 124, 144, EOS (up to Week 164)
Secondary Percentage Change From Baseline in the Adapted ACR Pediatric Criteria of Canakinumab Over Time: ACR Component: Standardized C-Reactive Protein (CRP) ACR component, Standardized CRP is the sixth response variable in the ACR ped criteria. CRP values were standardized to a normal range of 0 to 10 mg/L. Baseline, Weeks 4, 8, 28, 48, 96, 144, EOS (up to Week 164)
Secondary Percentage of Participants Who Had Flares With Canakinumab Treatment Over Time Flare was defined by at least 1 of the following: Reappearance of SJIA-related (e.g., not due to infection) fever (> 38°C) lasting for at least 2 consecutive days &/OR Flare according to the JIA pediatric criteria for flare (all criteria must be met): = 30% worsening in at least 3 of the 6 response variables and = 30% improvement in at not more than 1 of the 6 response variables if the physician's or parent's global assessment is 1of 3 response variables used to define flare, worsening of = 20 mm must be present, if the number of active joints or joints with limitation of motion is one of 3 response variables used to define flare, worsening in = 2 joints must be present if CRP is used to define flare, CRP must be > 30 mg/L > Day3, to <= Week 124
Secondary Percentage of Participants Who Achieved Inactive Disease (With and Without Duration of Morning Stiffness) With Canakinumab Treatment Over Time Inactive disease was defined as meeting all of the following: No joints with active arthritis; No fever (body temperature = 38°C); No rheumatoid rash, serositis, splenomegaly, hepatomegaly or generalized lymphadenopathy attributable to JIA; Normal CRP; Physician's global assessment of disease activity score = 10 mm Weeks 4, 8, 28, 48, 96, 144, EOS (up to Week 164)
Secondary Percentage of Participants With Canakinumab Treatment Who Were Able to Taper Corticosteroids Successfully Over Time To evaluate the percentage of participants with canakinumab treatment who were able to taper corticosteroids successfully over time Weeks 28, 48, 96, 144, EOS (up to Week 164)
Secondary Absolute Change From Baseline of Corticosteroids Dose Reduction With Canakinumab Treatment Over Time To evaluate the change from baseline of corticosteroids dose reduction with canakinumab treatment over time Baseline, Weeks 28, 48, 96, 144, EOS (up to Week 164)
Secondary Serum Concentration of Canakinumab To evaluate serum concentration (mean, standard deviation) of canakinumab. Baseline, Weeks 4, 24, 48, 72, 96, EOS (up to Week 164)
Secondary Pharmacodynamics (PD) Assessment: Total IL-1 Beta To evaluate serum total IL-1 Beta concentration by visit. Baseline, Weeks 4, 24, 48, 72, 96, EOS (up to Week 164)
See also
  Status Clinical Trial Phase
Completed NCT00891046 - An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. Phase 3
Completed NCT01304420 - Ultrasonography in Juvenile Idiopathic Arthritis Phase 0
Completed NCT02334748 - A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies Phase 3
Completed NCT01803321 - Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA) Phase 1
Completed NCT00144664 - Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) Phase 3
Completed NCT00144599 - Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) Phase 3
Terminated NCT00886769 - Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) Phase 3
Completed NCT00144612 - Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) Phase 3
Withdrawn NCT01676948 - An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) Phase 3
Recruiting NCT04088396 - A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) Phase 3
Recruiting NCT05027373 - Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection Phase 1